Vaccine Cuts Melanoma Recurrence Nearly in Half: A personalized mRNA cancer vaccine developed by Moderna and Merck – when combined with the immunotherapy drug Keytruda – significantly reduced the risk of melanoma recurrence, new research shows. The study found a 49% reduction in recurrence among patients with high-risk… #CancerResearch #Melanoma #Immunotherapy #mRNAVaccine #Keytruda
Leave a Reply